LigoCyte Pharmaceuticals Inc
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2012 | $2 M | No. 4 | $2 to $10 million | equity, debt, options | SEC | |
| Jun 2011 | $6 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Apr 2010 | $7 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Mar 2008 | $29 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
LigoCyte Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Jun 2012).
SEC Form D · Jun 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2012
That is all the official record says: LigoCyte Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of LigoCyte Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| C. Boyd Clarke | Executive officer | Jun 2012 |
| Donald Beeman | Executive officer | Jun 2012 |
| Larry Mikkola | Executive officer | Jun 2012 |
| Robert Goodwin | Executive officer | Jun 2012 |
| Donald P. Beeman | Executive officer | Aug 2009 |
| Rob Goodwin | Executive officer | Aug 2009 |
| Ben Auspitz | Director | Jun 2012 |
| C. Boyd Clarke | Director | Jun 2012 |
| Donald Beeman | Director | Jun 2012 |
| Hironori Boyd Hozoji | Director | Jun 2012 |
| Ivor Royston | Director | Jun 2012 |
| J. Donald deBethizy | Director | Jun 2012 |
| Markus Boyd Goebel | Director | Jun 2012 |
| George Boyd Kemble | Director | Jun 2011 |
| Donald P. Beeman | Director | Aug 2009 |
| George Kemble, Ph.D. | Director | Aug 2009 |
| Hironori Hozoji | Director | Aug 2009 |
| Ivor Royston, M.D. | Director | Aug 2009 |
| J. Donald deBethizy, Ph.D. | Director | Aug 2009 |
| Markus Goebel, M.D., Ph.D. | Director | Aug 2009 |